Go, no-go decision making for phase 3 clinical trials: ACT IV revisited – Authors' reply

Michael Weller, Nicholas Butowski, David D. Tran, Lawrence D. Recht, Michael Lim, Hal Hirte, Lynn Ashby, Laszlo Mechtler, Samuel A. Goldlust, Fabio Iwamoto, Jan Drappatz, Donald M. O'Rourke, Mark Wong, Mark G. Hamilton, Gaetano Finocchiaro, James Perry, Wolfgang Wick, Jennifer Green, Yi He, Christopher D. TurnerMichael J. Yellin, Tibor Keler, Thomas A. Davis, Roger Stupp, John H. Sampson

Research output: Contribution to journalLetter

3 Scopus citations
Original languageEnglish (US)
Pages (from-to)e709-e710
JournalThe Lancet Oncology
Volume18
Issue number12
DOIs
StatePublished - Dec 2017

ASJC Scopus subject areas

  • Oncology

Cite this

Weller, M., Butowski, N., Tran, D. D., Recht, L. D., Lim, M., Hirte, H., Ashby, L., Mechtler, L., Goldlust, S. A., Iwamoto, F., Drappatz, J., O'Rourke, D. M., Wong, M., Hamilton, M. G., Finocchiaro, G., Perry, J., Wick, W., Green, J., He, Y., ... Sampson, J. H. (2017). Go, no-go decision making for phase 3 clinical trials: ACT IV revisited – Authors' reply. The Lancet Oncology, 18(12), e709-e710. https://doi.org/10.1016/S1470-2045(17)30856-2